We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Stay up to date on the topics that matter to you

Image of Laura Elizabeth Lansdowne

Laura Elizabeth Lansdowne

Managing Editor

at Technology Networks

As managing editor, Laura works with the associate editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She oversees the in-house editorial team and works directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.

Got a question for Laura Elizabeth Lansdowne?

Get in touch using the contact form linked here and we’ll get back to you shortly

Published Content

Total: 401

DNA Analysis at the Single-Nuclei Level content piece image

Industry Insight

DNA Analysis at the Single-Nuclei Level

We spoke with Yan Zhang, PhD, CEO of Mission Bio to find out more about single-nuclei DNA analysis using the Tapestri platform.

Cancer Immunotherapy content piece image

Cancer Immunotherapy

Immunotherapy is a specific type of treatment that utilizes the body’s immune system to fight diseases such as cancer. Download this infographic to discover various types of immunotherapy and the potential of mRNA technology in this space.

Improving Drug–Receptor Interactions To Make Medicines Work Better content piece image

Improving Drug–Receptor Interactions To Make Medicines Work Better

Technology Networks had the pleasure of speaking with Laura Heitman, professor of molecular pharmacology within the Division of Drug Discovery and Safety at the Leiden Academic Centre for Drug Research (LACDR), Leiden University, to learn more about her research focused on drug–target kinetics.

Drug–Target Binding: Recent Research Developments content piece image

Drug–Target Binding: Recent Research Developments

Being able to accurately predict drug–target interactions (DTIs) and drug–target binding affinity (DTBA) is crucial in early drug development and during drug repurposing endeavors. Here, we look at some recent research developments in this space.

Ferrets Trained To Detect Avian Flu in Duck Poo content piece image

Ferrets Trained To Detect Avian Flu in Duck Poo

Researchers have trained male ferrets to detect a specific odor signature in feces from ducks infected with low pathogenic avian influenza A virus (LPAI). The study was published in PLoS ONE.

Accelerating the Commercialization of COVID-19 Neutralizing Antibodies With Plant-Based Manufacturing content piece image

Industry Insight

Accelerating the Commercialization of COVID-19 Neutralizing Antibodies With Plant-Based Manufacturing

The biotechnology company Angany recently announced the successful production of neutralizing monoclonal antibodies (NAbs) derived from the plasma of COVID-19 patients using its plant-based system. Angany has now joined forces with global technology company Phylloceuticals to leverage its plant-made commercial production system, to rapidly scale up commercial manufacturing.

COVID-19 Vaccine Prioritization and the Impact of Non-Pharmaceutical Interventions content piece image

COVID-19 Vaccine Prioritization and the Impact of Non-Pharmaceutical Interventions

To effectively reduce SARS-CoV-2 transmission and improve long-term health, tactical delivery of COVID-19 vaccines is essential. This was the conclusion of a recent study published in PLOS Computational Biology. A team of UK-based researchers found that prioritizing the distribution of the vaccine to at-risk groups, including the elderly and those with underlying health conditions, had the greatest impact in terms of minimizing the number of lives lost to the disease.

Composition of a Baby’s First Poop Provides Clues on Risk of Developing Allergies content piece image

Composition of a Baby’s First Poop Provides Clues on Risk of Developing Allergies

The composition of a newborn’s first stool can reveal whether they are likely to develop allergies within their first year of life, according to a new study, published in Cell Reports Medicine.

ABP-300: A Neutralizing Antibody Treatment for COVID-19 content piece image

Industry Insight

ABP-300: A Neutralizing Antibody Treatment for COVID-19

Technology Networks recently had the pleasure of speaking with Abpro’s CEO, Ian Chan, to learn more about the company’s research and development pipeline. Chan discusses in detail the development of ABP-300, a monoclonal antibody that neutralizes SARS-CoV-2 by associating with the virus’s spike protein.

A Step Closer to Orally-Delivered Insulin for Diabetes content piece image

A Step Closer to Orally-Delivered Insulin for Diabetes

A new technology developed within the Trabolsi Research Group at NYU Abu Dhabi (NYUAD) is a step closer to an oral delivery system for insulin therapy that could replace traditional subcutaneous injections. Technology Networks spoke with the research team to find out more.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter